Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
María Teresa Álvarez Román, Olga Benítez, Maria Isabel Canaro, María Fernanda López Fernández, Francisco J. López Jaime, José Mateo Arranz, Ramiro Núñez, Manuel Rodríguez López, Cristina Sierra Aisa & Victor Jiménez-Yuste. (2021) Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa. Expert Opinion on Biological Therapy 21:9, pages 1165-1171.
Read now
Read now
Nanxin Li, Eileen K. Sawyer, Konrad Maruszczyk, Greg Guzauskas, Marta T. Slomka, Tom Burke, Antony P. Martin, Jamie O’Hara, Matt Stevenson & Michael Recht. (2021) Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model. Journal of Medical Economics 24:1, pages 363-372.
Read now
Read now
Articles from other publishers (9)
Robert Klamroth, Ashley Bonner, Keith Gomez, Paul E. Monahan, Kirk Szafranski, Xiang Zhang, Sarah Walsh, Di Wang & Songkai Yan. (2023) Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half‐life factor IX therapies for severe or moderately severe haemophilia B. Haemophilia.
Crossref
Crossref
María Teresa Álvarez-Román, Raquel Díaz Merchán, Roberto Carlos Raynero Mellado & Victor Jiménez-Yuste. (2023) Switching and increasing prophylaxis regimen with a genetically recombinant fusion of coagulation factor IX and albumin in haemophilia B: a case report. Current Opinion in Hematology 30:5, pages 175-179.
Crossref
Crossref
Tom Burke, Anum Shaikh, Talaha M. Ali, Nanxin Li, Barbara A. Konkle, Declan Noone, Brian O'Mahony, Steven Pipe & Jamie O'Hara. (2022) Association of factor expression levels with annual bleeding rate in people with haemophilia B. Haemophilia 29:1, pages 115-122.
Crossref
Crossref
Johnny N. Mahlangu, Jose Luis Lamas, Juan Cristobal Morales, Daniel R. Malan, Silva Zupančić Šalek, Michael Wang, Lisa N. Boggio, Inga Hegemann, Andrzej Mital, Matthew Cardinal, Tong Zhu, Pengling Sun & Steven Arkin. (2022) A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. British Journal of Haematology 200:2, pages 229-239.
Crossref
Crossref
Miguel Escobar, Maria Elisa Mancuso, Cedric Hermans, Cindy Leissinger, Wilfried Seifert, Yanyan Li, William McKeand & Johannes Oldenburg. (2022) IDELVION: A Comprehensive Review of Clinical Trial and Real-World Data. Journal of Clinical Medicine 11:4, pages 1071.
Crossref
Crossref
Sergei Spitsin, Bruce C. Schnepp, Mary J. Connell, Tehui Liu, Christine M. Dang, Vasiliki Pappa, Richard Tustin, Annemarie Kinder, Philip R. Johnson & Steven D. Douglas. (2020) Protection against SIV in Rhesus Macaques Using Albumin and CD4-Based Vector-Mediated Gene Transfer. Molecular Therapy - Methods & Clinical Development 17, pages 1088-1096.
Crossref
Crossref
Maria Elisa Mancuso, Aaron Lubetsky, Brigitte Pan‐Petesch, Toshko Lissitchkov, Azusa Nagao, Wilfried Seifert, Yanyan Li & Elena Santagostino. (2020) Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B. Journal of Thrombosis and Haemostasis 18:5, pages 1065-1074.
Crossref
Crossref
Yvonne Brennan, Sumit Parikh, Simon McRae & Huyen Tran. (2020) The Australian experience with switching to extended half‐life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation. Haemophilia 26:3, pages 529-535.
Crossref
Crossref
Seohyun (Claudia) Choi, Michael Casias, Danielle Tompkins & Jimmy Gonzalez. 2020. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
317
336
.